Virgilio Edoardo, Giarnieri Enrico, Giovagnoli Maria Rosaria, Montagnini Monica, Proietti Antonella, D'Urso Rosaria, Fegiz Alessandra, Mercantini Paolo, Balducci Genoveffa, Cavallini Marco
Department of Medical and Surgical Sciences and Translational Medicine, Faculty of Medicine and Psychology, University "Sapienza", St. Andrea Hospital, Rome, Italy
Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, University "Sapienza", St. Andrea Hospital, Rome, Italy.
Anticancer Res. 2019 Feb;39(2):1019-1027. doi: 10.21873/anticanres.13208.
BACKGROUND/AIM: Although reckoned necessary for survival benefit, neoadjuvant chemotherapy (NAC) of gastric cancer (GC) patients has so far provided questionable results. Consequently, searching for new and clearer systems of response to NAC, post-NAC re-evaluation and prognostic prediction appears essential. The purpose of this study was to examine endogastric cytopathology and hemoglobin level count as new features, potentially useful for GC patients after NAC.
Between April 2012 and October 2018, 21 of 116 patients with resectable GC received NAC and were investigated for the presence of free-floating malignant cells in their gastric lavage (yGL1) and the development of hypohemoglobinia (yAnemia).
yGL1 and yAnemia were found in 11 and 12 patients, respectively. yGL1 correlated with the traditional parameters of tumor regression (p=0.0424). Both yGL1 and yAnemia were found to be independent predictive factors of overall and progression-free survival (p≤0.0364).
In the light of our results, the yGL1 and yAnemia appear two promising, simple and interesting clinicopathological features which should always be examined for better clarifying GC patients' response to NAC.
背景/目的：尽管人们认为新辅助化疗（NAC）对胃癌（GC）患者的生存有益，但迄今为止其效果仍存在疑问。因此，寻找新的、更清晰的NAC反应系统、NAC后重新评估及预后预测方法显得至关重要。本研究旨在探讨胃内细胞病理学和血红蛋白水平计数作为新特征，对接受NAC后的GC患者可能具有的作用。
2012年4月至2018年10月期间，116例可切除GC患者中有21例接受了NAC，并对其洗胃液中游离恶性细胞的存在情况（yGL1）和血红蛋白过低情况（y贫血）进行了调查。
分别在11例和12例患者中发现了yGL1和y贫血。yGL1与肿瘤退缩的传统参数相关（p=0.0424）。yGL1和y贫血均被发现是总生存期和无进展生存期的独立预测因素（p≤0.0364）。
根据我们的研究结果，yGL1和y贫血似乎是两个有前景、简单且有趣的临床病理特征，在评估GC患者对NAC的反应时应始终进行检查以获得更清晰的认识。
